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PEGylated gold nanoparticles are decorated with various amounts
of human transferrin (Tf) to give a series of Tf-targeted particles
with near-constant size and electrokinetic potential. The effects of
Tf content on nanoparticle tumor targeting were investigated in
mice bearing s.c. Neuro2A tumors. Quantitative biodistributions of
the nanoparticles 24 h after i.v. tail-vein injections show that the
nanoparticle accumulations in the tumors and other organs are
independent of Tf. However, the nanoparticle localizationswithin a
particular organ are influenced by the Tf content. In tumor tissue,
the content of targeting ligands significantly influences the number
of nanoparticles localizedwithin the cancer cells. In liver tissue, high
Tf content leads to small amounts of the nanoparticles residing in
hepatocytes, whereas most nanoparticles remain in nonparenchy-
mal cells. These results suggest that targeted nanoparticles can
provide greater intracellular delivery of therapeutic agents to the
cancer cells within solid tumors than their nontargeted analogs.
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Targeted nanoparticle delivery of therapeutic molecules hasthe potential to provide safer and more effective therapies
for cancer applications (1). Recent work has focused on under-
standing the parameters that influence targeted nanoparticle
behavior and the development of design rules for creating
nanoparticle-based therapeutics and imaging agents. Passive
tumor targeting takes advantage of the irregularity and leakiness
of tumor vasculature to allow nanoparticle accumulation in the
tumor (caused by the enhanced permeability and retention
effect) (2, 3). Active targeting exploits the (over)expression of
surface receptors on cancer cells by providing targeting ligands
that can engage these receptors. Previous studies on active tar-
geting have used an assortment of ligands ranging from proteins
[antibodies (4) and their molecular fragments (5)], nucleic acids
[aptamers (6)], and small molecules [vitamins (7), peptides (8),
or carbohydrates (9)]. Ligand incorporation facilitates the entry
of nanoparticles to cancer cells via receptor-mediated endocy-
tosis, after which they can release their drug payloads to provide
a therapeutic action. Perrault et al. (10) convincingly illustrated
that PEGylated gold nanoparticles (AuNPs) must be <100 nm in
diameter to move away from the vasculature and throughout the
tumor. This condition is necessary for engaging cancer cell sur-
face receptors and attacking molecular targets within cancer
cells. Park et al. (11) showed that antibody-targeted liposomes
had enhanced antitumor effects as compared with their untar-
geted counterparts. The same investigators later concluded that
the antibody targeting does not increase accumulation of lip-
osomes in tumor as compared with untargeted controls but
rather increases the particle localization within cancer cells (12).
Using multimodal in vivo imaging techniques, Bartlett et al. (13)
demonstrated that untargeted and transferrin (Tf)-targeted
polymeric nanoparticles containing siRNA have the same whole-
body distribution (and kinetics) and accumulation in tumor, but
the targeted particles lead to more pronounced gene inhibition
within cancer cells. Very recently, with the aid of computer
simulations, Schmidt and Wittrup (14) predicted similar uptake
in tumor of both targeted and untargeted liposomes ∼50 nm in
size. These examples indicate that the targeting ligand does not
influence organ distribution (e.g., bulk tumor localization) but
instead influences distribution within tumor tissue (i.e., in cancer
cells versus non-cancer cells such as leukocytes and blood
endothelial cells). These findings suggest that active targeting of
nanoparticles occurs via a mechanism different from that of
individual targeting ligands (e.g., antibodies). Thus, further
examination of active targeting with nanoparticles is merited. We
prepared a series of AuNPs with Tf contents spanning two orders
of magnitude for comparison with untargeted particles to test the
mechanistic effects of the active targeting of nanoparticles in
solid tumors and to delineate particle distribution patterns
caused by ligand targeting at the cellular level, a level not
investigated in previous organ and tissue distribution studies.
AuNPs provide a well-defined, rigid core for surface mod-
ification with Tf. Gold has a low level of in vivo toxicity (15), and
scalable synthesis of AuNPs with tunable dimensions is
straightforward (16). With the “silver enhancement” method,
AuNPs catalyze the selective surface deposition of metallic sil-
ver, enabling their visualization as size-enhanced entities in tis-
sue sections under light microscopy (17). Additionally, the high
electron density of AuNPs permits the direct visualization of
their cellular localization with transmission electron microscopy.
The combination of these imaging methods, when used together
with inductively coupled plasmonic mass spectrometry (ICP-MS)
that can be employed to measure organ-level gold content (18),
renders AuNPs a versatile imaging platform for the top-down
elucidation of the nanoparticle biodistribution on organ, tissue,
and (sub)cellular levels.
The decoration of AuNPs with thiolated poly(ethylene glycol)
(PEG-SH) via the formation of stable, covalent gold–thiol link-
ages (bond energy = 30–40 kJ/mol) (19) can reduce nonspecific
interactions (20), allowing the targeting ligands immobilized on
the particle surface to engage cell surface receptors with high
specificity. PEGylation also prolongs the circulation time of
nanoparticles (21), giving sufficient time for particles to localize
in different organs.
Human holo-Tf is the targeting ligand used here to probe the
effects of active targeting. Because of rapid cell division and
stringent demand for iron (for heme synthesis), many cancer cell
types have abundant expression of Tf receptors (TfRs) (22). Tf is a
79-kDa endogenous glycoprotein that binds to TfRs at ex-
tracellular pH (Kd = 1–100 nM) (23, 24) and triggers receptor-
mediated endocytosis (25). It has a history of use as a targeting
agent for cancer cells. For example, Tf-targeted siRNA-containing
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nanoparticles markedly inhibit tumor growth in metastatic Ewing’s
sarcoma, whereas their untargeted counterparts do not (26).
The covalent conjugation of Tf onto PEG-AuNPs at varying
amounts to form Tf -targeted, PEGylated gold nanoparticles (Tf-
PEG-AuNPs) and the i.v. injection of these particles into mice
bearing s.c. Neuro2A tumors provide the model system for inves-
tigating the effects of targeting ligand content on in vivo particle
distribution at the organ, tissue, and cellular levels.
Results and Discussion
Synthesis and Characterization of Tf-PEG-SAc. Fig. 1A illustrates the
synthesis scheme for Tf-PEG-SAc, a PEG conjugate [molecular
weight (MW): 5,000] that contains the targeting ligand (Tf) and an
acetyl-protected sulfur group (SAc). This conjugate decorates the
surface of the gold nanoparticles to extend Tf away from the gold
surface to the nanoparticle periphery, as well as to facilitate the
engagement of Tf with surface TfRs of cancer cells within the
tumor. Purification of the crude reaction mixture using hydro-
phobic interaction chromatography (HIC) gave pure, mono-
PEGylated Tf-PEG-SAc with an apparent molecular weight of 84
kDa (Fig. S1). This PEGylation method is not site-specific on the
Tf, so excessive protein PEGylationmay block the active sites of Tf
for binding to TfRs. Therefore, we used only themono-PEGylated
fraction for nanoparticle assembly. The competitive binding of Tf-
PEG-SAc against Tf conjugated toAlexaFluor488 (Tf-AF488)was
used to estimate the effects of mono-PEGylation on Tf binding
affinity (Fig. 1B), with holo-Tf and methoxy-PEG-thiol (mPEG-
SH; MW: 5,000) as positive and negative controls, respectively. A
1:1 ratio of Tf-AF488 to free holo-Tf gives an ∼45% reduction in
fluorescence, suggesting that Tf-AF488 and free holo-Tf have
almost equal binding affinity. Tf-PEG-SAcfluorescence is reduced
as the Tf-PEG-SAc concentration increases, although the magni-
tude of the reduction is less than that of free holo-Tf. A 1:1 ratio of
Tf-AF488 to Tf-PEG-SAc gives an ∼20% decline in fluorescence.
Thus, mono-PEGylation does alter the affinity of Tf to TfRs on
Neuro2A cells but not to a large extent. Furthermore, a saturation
binding experiment of Tf-AF488 to TfRs of Neuro2A cells was
used tomeasure the affinity of Tf-PEG-SAc (Fig. 1C). A Scatchard
analysis of these data yields a Kd for Tf-AF488 of 64 nM (Fig. S2B)
andhence aKd of 64 nM for free holo-Tf (based on the competitive
binding study). The estimated Kd for Tf-PEG-SAc is 144 nM,
because thebinding affinity ofTf-PEG-SAc toTfRs is 2.25-fold less
than that of free holo-Tfs.
Synthesis and Characterization of Tf-PEG-AuNPs. The addition of Tf-
PEG-SH (deprotected Tf conjugate) into an aqueous suspension
of 50-nm unmodified AuNPs (condition I) initiates the assembly
of Tf-PEG-AuNPs (Fig. 2). We selected this gold particle size to
mimic the size of our siRNA-containing therapeutic nano-
particles (∼70 nm) (13, 26) and to achieve optimal receptor-
mediated endocytosis in cells amid other particle sizes in the 10-
to 100-nm range (27). Adjustment of input ligand concentration
during the assembly process gave targeted nanoparticles with Tf
contents spanning two orders of magnitude [conditions III (2 Tf
per particle), IV (18 Tf per particle), and V (144 Tf per par-
ticle)], with a coupling efficiency that decreases with input Tf
concentration from 87% (III) to 60% (V) (Table S1). Complete
PEGylation with excess mPEG-SH followed to mask any
unreacted gold surface of the nanoparticles. PEGylated nano-
particles (condition II) were prepared for use as an untargeted
control. Table 1 lists the physicochemical properties of the
nanoparticles. Hydrodynamic diameters of Tf-PEG-AuNPs are
near-constant in water and 1× PBS independent of Tf content
(∼80 nm). Their electrokinetic (ζ) potentials in 1 mM KCl are
also the same and are independent of Tf content (∼−10 mV).
With an isoelectric point of 5.9 (25), Tf is negatively charged in
1× PBS (pH 7.4), but the overall particle ζ potential does not
change significantly with Tf content. Thus, this set of nano-
particles is well suited to ascertain the effects of targeting ligand
content on nanoparticle distribution at relatively constant
nanoparticle diameter and ζ potential.
Fig. 1. Synthesis and characterization of Tf-PEG-SAc. (A) Reaction conditions:
(i) SATA, 4 h, DMF, room temperature; (ii) DSC, DMF/dioxane, 4 h, room
temperature; (iii) Holo-Tf, 2 h, room temperature, 50 mM sodium phosphate
(pH 7.4); (iv) hydroxylamine, 2 h, room temperature, 50 mM sodium phos-
phate, 25mMEDTA (pH 7.5). Step iv renders free thiol groups for conjugation
onto AuNPs to form Tf-PEG-AuNPs. (B) Competitive binding assay. PEGylation
to form Tf-PEG-SAc did not drastically reduce the binding affinity of Tf.
Reported data are expressed as the percent of fluorescence of cells incubated
onlywith Tf-AF488. (C) Saturation binding of Tf-AF488 to Neuro2A cells. Error
bars represent 1 SD from duplicate experiments.
Fig. 2. Synthesis of Tf-PEG-AuNPs. Unmodified 50-nm AuNPs (I) were
reacted with excess mPEG-SH to form PEG-AuNPs (II) as untargeted particles
or first were reacted with various amounts of Tf-PEG-SH and later excess
mPEG-SH to form Tf-PEG-AuNPs (III: 2 Tf per particle; IV: 18 Tf per particle; V:
144 Tf per particle).
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Stability and Binding Affinity of Tf-PEG-AuNPs. Particle stability in
physiological conditions is a prerequisite for effective active tar-
geting. Unmodified AuNPs (I) aggregate rapidly in 1× PBS (Fig.
3A). PEGylation imparts steric stability to II–V in salt solutions, as
can be seen from their nearly constant hydrodynamic diameter
(HD) when exposed to 1× PBS (Fig. 3A). Moreover, II–V do not
flocculate in 90% fresh mouse serum in 1× PBS (Fig. 3B). These
results strongly suggest that the PEGylated nanoparticles will not
aggregate in vivo. From the saturation binding experiment of Tf-
PEG-AuNPs, IV and V bind to Neuro2A cells in a fashion that
depends on both Tf content and nanoparticle concentration (Fig.
3C), validating the successful conjugation of Tf-PEG-SH onto the
particle surface. A Scatchard analysis was used to estimate the Kd
of Tf-PEG-AuNPs, assuming a homogeneous distribution of Tf on
the nanoparticle surface. The measured values of IV and V were
1.06 and 0.13 nM, respectively. If, because of geometric scaling
considerations, 21.33%of the Tf on the particle surface is in actual
contact with TfRs on the surface of Neuro2A cells (Fig. S3), the
resultant Kds of IV and V are 0.23 and 0.03 nM, respectively,
representing ≈600-fold and 4800-fold enhancement in binding
affinity, respectively, compared with free Tf-PEG-SAc (Kd = 144
nM) (Table S2 and Fig. S4). The magnitude of binding affinity
enhancement also increases with the ligand content on the particle
surface. Such enhancement underscores the multivalent effect
that occurs when particle curvature permits localized surfaces of
multiple Tfs to interact simultaneously with surfaceTfRs to trigger
endocytosis. Furthermore, given the low binding affinity, the poor
signal-to-noise ratio from thebinding data of III does notwarrant a
meaningful estimation of the Kd for III. In theory, with such dilute
Tf content (2 Tf per particle), the binding affinity of III should
approach that of the monovalent ligand, Tf-PEG-SAc (Kd =
144 nM).
In Vivo Tumor Distribution of Tf-PEG-AuNPs. Mice bearing s.c.
Neuro2A tumors received i.v. administration of II–V via the tail
vein and were euthanized 24 h later to collect organs for anal-
yses. Despite the overexpression of surface TfRs by Neuro2A
cells (Fig. S2A) at the organ level, the tumor amasses only 2–3%
of the injected dose (ID) of particles, independent of Tf content
(Fig. 4). At the tissue level, histological examination reveals
predominant localization of AuNPs in the vicinity of leukocytes
for all Tf contents (Fig. 5 A–B1). Intracellular accumulation of
nanoparticles inside Neuro2A cells is rare (Fig. 5 B–C1) at
low Tf content (II–IV), but a further increase in Tf content to
144 Tf per particle leads to considerable nanoparticle uptake by
Neuro2A cells, as seen from isolated nanoparticles of V residing
near Neuro2A cells (Fig. 5D1). Electron microscopy reveals clear,
Tf content-dependent, intracellular nanoparticle localization.
Although II–IV localize mostly inside leukocytes (Fig. 5A2) or
externally touch the surface of Neuro2A cells (Fig. 5 B–C2),
clusters of V reside within large endocytic vesicles of Neuro2A
cells (Fig. 5D2). The abundance of mitochondria and endoplasmic
reticulum (essential for robust cellular metabolic activities) indi-
cates nanoparticle localizations inside target Neuro2A cells but
not inside other leukocytes, endothelial cells, or other noncancer
cells (Fig. 5D3). Thus, ligand content does not alter the extent of
bulk nanoparticle content in the tumor. Instead, it biases the tissue
and cellular distribution with increasing targeting ligand content
favoring the intracellular localization within cancer cells. These
results support the work of Kirpotin et al. (12) and our previous
observations from the targeted delivery of siRNA (13). Fur-
thermore, III and IV demonstrate the same in vivo distribution
patterns within the tumor as II. Therefore, a critical Tf content is
necessary to promote intracellular accumulation of nanoparticles
in cancer cells.
In Vivo Hepatic Distribution of Tf-PEG-AuNPs. Because nanoparticles
always localize in liver to some extent, we address the fate of Tf-
PEG-AuNPs in the liver. Compared with Neuro2A cells, hep-
atocytes have weaker expression of TfRs. At the organ level, Tf
content does not influence the level of nanoparticle localization
in the liver (17–21% ID) (Fig. 4). At the tissue level, most par-
ticles (independent of Tf content) experience phagocytic uptake
by Kupffer cells (Fig. 6B2) or reside along hepatic sinusoids (Fig.
6 A–D1) or in the space of Disse, a region between hepatocytes
Table 1. Physicochemical properties of AuNPs
NP HD-water(nm) HD-1xPBS(nm) ZP(mV) Tf content(# Tf/particle)
I 49.4 ± 0.6 755.4 ± 8.7 −18.3 ± 1.2 N/A
II 73.2 ± 1.3 74.9 ± 0.9 −10.9 ± 1.3 N/A
III 77.0 ± 0.9 77.7 ± 1.5 −10.8 ± 0.9 2.1 ± 0.2
IV 78.5 ± 1.7 81.3 ± 2.9 −9.0 ± 1.7 17.5 ± 2.5
V 81.0 ± 2.5 87.5 ± 3.4 −9.9 ± 1.7 144.3 ± 15.6
I, unmodified AuNP; II, PEG-AuNP; III–V, Tf-PEG-AuNP of 2, 18, and 144 Tf
per particle, respectively; HD, hydrodynamic diameter; N/A, not applicable;
NP, nanoparticle; ZP, ζ potential in 1 mM KCl. The table presents data as
average ± SD from three experiments.
Fig. 3. Particle stability and binding. (A) In vitro stability against salt.
Unmodified 50-nm AuNPs (I) showed instant aggregation after the addition
of PBS at the fourth minute, but II–V remained stable. (B) In vitro stability
against serum. PEGylation attenuated particle aggregation in 90% mouse
serum. (C) Saturation binding of Tf-PEG-AuNPs to Neuro2A cells. Tf-PEG-
AuNPs bound in a Tf content-dependent manner (III–V). Error bars indicate 1
SD from duplicate experiments.
Fig. 4. In vivo organ distribution. Bulk particle localization in all organs was
independent of Tf content. Gold contents are normalized to % injected
dose. Error bars indicate 1 SD from each Tf-PEG-AuNP class (n = 3).
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and blood endothelial cells that contains reticular fibers, micro-
villi, and collagen (Fig. 6A3). Tf-PEG-AuNPs rarely enter hep-
atocytes (independent of Tf content) (Fig. 6A2). As in tumor, Tf
targeting does not affect bulk particle content in the liver but
yields infrequent instances of accumulation inside hepatocytes,
given sufficiently high Tf content. From electron micrographs, at
the cellular level, IV and V reside inside vesicles as small clusters
near the hepatocyte nucleus, surrounded by mitochondria and
endoplasmic reticulum (Fig. 6 C2–3 and D2). Below the
threshold Tf content, however, II and III never permeate the
space of Disse and enter hepatocytes. Thus, the Tf targeting
ligand content does not alter the extent of bulk content in the
liver; it only biases particle localization nearby and entry
into hepatocytes.
In summary, our results demonstrate the use of Tf-PEG-
AuNPs as imaging agents to understand targeted nanoparticle
behavior in vivo. With similar sizes and ζ potentials, targeted
particles of different Tf contents (II–V) permit the investigation
of the effect of targeting ligand content on nanoparticle dis-
tribution in vivo. PEGylation confers steric stability against salt-
and serum-induced aggregation in vitro. Because II–V localize
in cellular structures of the tumor and liver as individual entities,
it is suggested that the steric stabilization occurs in vivo as well.
Despite complete nanoparticle PEGylation, the organs of the
reticuloendothelial system (liver and spleen) still show sig-
nificant localization (17–21% ID and 5–6% ID, respectively) in
excess of that in tumor (2–3% ID), irrespective of Tf content.
Active targeting with Tf-PEG-AuNPs leads to nanoparticle
internalization into cancer cells that have abundant TfR
expression (Neuro2A cells). These data, when taken together
with past tumor permeation work conducted with other targeted
nanoparticle delivery systems [dextran (11), immunoliposomes
(12), and Tf-targeted cyclodextrin (13)], support the conclusion
that targeted nanoparticles <100 nm in size always deliver a
higher payload (drug, imaging agent, or combination) into
cancer cells of the tumor than their untargeted counterparts.
Furthermore, the present study indicates that there is a mini-
mum targeting ligand content on the nanoparticle that provides
adequate conditions for effective active targeting. Below this
content threshold, targeted nanoparticles manifest in vivo dis-
tribution patterns similar to those of untargeted particles at the
organ, tissue, and cellular levels. To achieve effective intra-
cellular targeting of cancer cells in solid tumors, our results
underscore the importance of optimizing the ligand content on
the nanoparticle surface rather than simplistically switching
nanoparticles from an “off” state to an “on” state, (i.e., untar-
geted vs. targeted nanoparticles).
Materials and Methods
Synthesis of Tf-PEG-Sac. HO-PEG-NH2 (MW: 5,000) (Laysan Bio) was reacted
with excess N-Succinimidyl-S-acetylthioacetate (SATA) (Pierce Biotechnology)
in dimethylformamide (DMF) at room temperature for 4 h. The product was
reacted with excess N, N-disuccinimidyl carbonate (DSC) (Pierce Bio-
technology) in DMF/dioxane at room temperature for 4 h to give NHS-PEG-
SAc. Upon solvent removal and drying in vacuuo, NHS-PEG-SAc was reacted
with Tf (Sigma) at a 2:5 molar ratio in 50 mM sodium phosphate at room
temperature for 2.5 h to form Tf-PEG-SAc. Purification involved passing the
Fig. 5. In vivo tumor tissue and
intracellular distribution. (A–
D1) Light micrographs of
“silver-enhanced” tumor sec-
tions. Arrows indicate “silver-
enhanced” AuNPs. (Scale bar,
10 μm.) Independent of Tf con-
tent,most particles resided near
leukocytes. Electron micro-
graphs show particles either
engulfed by leukocytes (A2) or
tangentially touching Neuro2A
cells (B–C2; enlarged image,B3).
(D2 and enlarged image, D3)
Particles with a high Tf content
(V: 144 Tf per particle) can enter
Neuro2A cells. ER, endoplasmic
reticulum; M, mitochondrion;
N2A, Neuro2A cell; Nu, nucleus;
RBC, red blood cell; V, vesicle;
WBC, leukocyte. [Scalebars:A1–
D2 (2 μm); B3 and D3 (500 nm).]
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reaction mixture through a 5-mL HiTrap Phenyl HIC column in ÄKTA FPLC
(GE Healthcare), with 1 M ammonium sulfate as the high-salt condition and
50 mM sodium phosphate as the low-salt condition.
Competitive Binding Assay. Plated in a 24-well plate at a population of 5 × 104
2 d in advance, Neuro2A cells were incubated in 0.45 mL of OptiMEM I
containing 50 nM Tf-AF488 and different amounts of Tf-PEG-SAc at 37 °C
and 5% CO2 for 1 h. After PBS rinses to remove unbound Tf conjugates, cells
were analyzed with FACSCalibur (Becton Dickinson Biosciences) to quantify
the mean fluorescence at 488 nm. The Tf on both Tf-PEG-SAc and Tf-AF488
bind to and compete for surface TfRs of Neuro2A cells. Reported data show
the percent of mean fluorescence of cells incubated with Tf-AF488 only. For
comparison, analogous experiments were conducted with holo-Tf and
mPEG-SH (MW: 5,000) (Sigma-Aldrich).
Binding of Tf-AF488 to Neuro2A Cells. Plated in a 24-well plate at a population
of 5 × 104 cells per well 2 days in advance mouse neuroblastoma (Neuro2A)
cells were incubated in 0.45 mL of OptiMEM I (Invitrogen) containing various
concentrations of Tf-AF488 at 37 °C and 5% CO2 for 1 h. After PBS rinses to
remove unbound Tf-AF488, cells were analyzed with FACSCalibur (BD Bio-
sciences) to quantify the mean fluorescence at 488 nm. A Scatchard analysis
gave the dissociation constant (Kd) of Tf-AF488 from TfRs of Neuro2A cells.
Assembly of Tf-PEG-AuNPs. The deprotection of 6 μL of 1-μg/μL Tf-PEG-SAc in
1× PBS was performed with the addition of 54 μL of 50 mM NH2OH in 50 mM
sodium phosphate and 25 mM EDTA (pH 7.5) at room temperature for 2 h.
The addition of deionized water to Tf-PEG-SH (the deprotected Tf con-
jugate) yielded a 0.3-mL volume for salt removal by a 0.5-mL Zeba Desalt
Spin Column (Thermo Scientific). Salt removal was necessary to prevent salt-
induced aggregation of AuNPs but led to 25% loss of Tf content because of
entrapment in the column. To prepare AuNPs with increasing Tf contents,
0.5 μL, 5 μL, or 50 μL of desalted Tf-PEG-SH (15 ng/μL) was added to 0.5 mL of
50-nm unconjugated AuNPs (Ted Pella) at a concentration of 4.5 × 1010
particles/mL The reaction proceeded at room temperature with shaking for
1 h. Complete PEGylation of the unreacted gold surface required the intro-
duction of 10 μL of 1 mMmPEG-SH (MW: 5,000) into the reaction mixture and
proceeded at room temperature with shaking for 30 min. The reaction mixture
was centrifuged at 14,000 × g for 10 min, followed by removal of the super-
natant fraction that contained unreacted or dimerized Tf- and methoxy-PEGs.
Tf-PEG-AuNPs sank to the bottom of the reaction vial as a brick red pellet. The
pellet was rinsed twice with 0.45 mL of 1× PBS for 10 min on a shaker. Also,
0.5 mL of 50-nm AuNPs was PEGylated with 10 μL of 1 mM mPEG-SH at room
temperature with shaking for 30 min. The removal of excess mPEG-SH yielded
PEG-AuNPs as untargeted control particles.
Physicochemical Characterizations. HD and ζ potential of AuNPs were meas-
ured using ZetaPals (Brookhaven Instruments Corporation). For HD meas-
urements, the particle pellet was resuspended in 1.2 mL of deionized water
or 1× PBS. Reported HDs are average values from three runs of 3 min each.
For ζ-potential analysis, the pellet was resuspended in 1.4 mL of 1 mM KCl.
Reported ζ potentials are average values from 10 runs each with a target
residual of 0.012 measured at a conductance of 320 ± 32 μS.
Estimation of Tf Content. A human Tf ELISA quantitation kit (Bethyl Labo-
ratories) was used to determine the amount of unbound Tf-PEG-SH in the
supernatant fractions collected from the synthesis and PBS rinsing steps. Given
the initial amount of Tf-PEG-SH added, a mass balance indirectly yields the Tf
contentofTf-PEG-AuNPs.Allreportedcontentsarefromtriplicateexperiments.
Particle Stability in Salt- and Serum-Containing Solutions. To monitor particle
stability in salt solutions, a pellet containing 2.25 × 1010 unmodified AuNPs
(I), PEG-AuNPs (no Tf: II), or Tf-PEG-AuNPs of different Tf contents (III: 2 Tf
Fig. 6. In vivo liver tissue and
intracellular distribution. (A–
D1) Light micrographs of
“silver-enhanced” liver sec-
tions. Arrows indicate “silver-
enhanced” AuNPs. (Scale bar,
10 μm.) Independent of Tf
content, particles rarely enter
hepatocytes. Electron micro-
graphs show particles either
engulfed by Kupffer cells (A2)
or residing in the space of Disse
(A2; enlarged image, A3). He-
patocytes can internalize par-
ticles with high Tf contents (IV
and V: C–D2; enlarged image:
C3). D, space of Disse; En,
endothelial cell; ER, endoplas-
mic reticulum; G, Golgi appa-
ratus; H, hepatocyte; HA,
hepatic artery; KC and red cir-
cle, Kupffer cell; M, mito-
chondrion; MV, microvillus; Nu,
nucleus; PV, hepatic portal
vein; RBC, red-blood cell; S,
sinusoid. [Scale bars: A1–D2
(2 μm; A3 and C3 (500 nm).]
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per particle; IV: 18Tf per particle; V: 144 Tf per particle) were resuspended in
1.26 mL of deionized water in a cuvette placed inside the ZetaPals instru-
ment. Four minutes into HD measurements, 0.14 mL of 10× PBS was added
to the cuvette. Size measurements continued for 16 more minutes. The
assessment of particle stability in serum entailed the resuspension of a pellet
containing 2.25 × 1010 particles of I–V in 200 μL of 90% fresh mouse serum
[collected by saphenous vein extraction from A/J mice (Jackson Laboratory)]
in 1× PBS. A Safire2 Microplate Reader (Tecan) was used to measure the
absorbance of the AuNP-serum mixture at 37 °C for 1 h at 590 nm, a
wavelength indicative of gold flocculation.
Binding of Tf-PEG-AuNPs to Neuro2A Cells. Plated in a 24-well plate at a
population of 8 × 105 cells per well 2 d in advance, Neuro2A cells were
incubated in 0.2 mL of OptiMEM I containing different concentrations of III–
V at 37 °C and 5% CO2 for 1 h. After PBS rinses to remove unbound particles,
a Safire2 Microplate Reader (Tecan) was used to measure the cell absorbance
at 530 nm, the plasmon peak of II. To account for nonspecific adsorption,
Neuro2A cells were incubated with identical concentrations of II. For
Scatchard analyses to deduce the effective Kds of III–V, the free gold con-
centration was quantified by Safire2 based on a calibration curve of known
concentrations of II. Reported values, after deduction of nonspecific gold
signals, are from duplicate experiments.
Cell Lines. Neuro2A cells were cultured at 37 °C and 5% CO2 in DMEM,
supplemented with 10% FBS, 100 U/mL penicillin, and 100 U/mL strepto-
mycin. Before tumor implantation, cells were washed with PBS, trypsinized,
and resuspended in serum-free, antibiotic-free DMEM.
Animal Models. All animal experiments complied with National Institute of
Health Guidelines for Animal Care and were approved by the California
Institute of Technology Institutional Animal Care and Use Committee. In the
right hind flank, each 8-week-old, female A/J mouse received s.c. implan-
tation of 106 Neuro2A cells in 0.1 mL of DMEM.
Systemic Administration. Two weeks after tumor implantation, four mouse
groups (n = 3) received i.v tail-vein administration of 4.5 × 1011 particles of
II V (in 0.5 mL of 5% glucose). Animals were euthanized by CO2 overdose 24
h after injection, followed by collection and immersion-fixation of the
tumor, liver, kidney, heart, spleen, and lung in 4% paraformaldehyde in 1×
PBS at 4 °C for 2 weeks.
ICP-MS. Homogenized organs were oxidized in 0.5 mL of acid mixture (70%
HNO3 and 35% HCl at a 3:1 volume ratio) in a microwave until they dissolved
fully. After the addition of 20.5 mL of deionized water, the sample was
centrifuged at 3200 × g for 15 min to remove cell debris, leaving the
supernatant for gold content analysis using an HP 4500 ICP-MS (Agilent).
Nebulization occurred with a flow of 1.3 L/min of argon using a Babbington
type nebulizer in a Pyrex Scott-type spray chamber. The argon plasma power
was 1200 W with a flow of 15 L/min and an auxiliary flow of 1.1 L/min. A
calibration curve of various concentrations of II was used to measure the
gold content, using 2.5% HNO3 and 0.42% HCl as the blank solvent and
tissues from uninjected A/J mice to account for background organ gold
content. Reported values are expressed as the percent of ID. Error bars
indicate 1 SD from three different mice in each mouse group.
Histology with Silver Enhancement. Tissue blocks (∼1 cm3) were dehydrated
gradually with ethanol and embedded in molten paraffin to generate sec-
tions 4 μm thick. Deparaffinized sections underwent silver enhancement (17)
to enlarge AuNPs for visualization under light microscopy and were counter
stained with Gill’s hematoxylin and 1% eosin in 95% ethanol.
Transmission Electron Microscopy. Tissue blocks (∼1 mm3) were fixed in 2.5%
glutaraldehyde (in 0.1 M sodium cacodylate, pH 7.4) for 2 h, stained by 1%
OsO4 at 4 °C for 2 h and 0.9% OsO4 and 0.3% K4Fe(CN)6 at 4 °C for 2 h.
Gradual dehydration with ethanol and propylene oxide enabled tissue
embedding in Epon 812 resins (Electron Microscopy Sciences). Sections 80 nm
thick were deposited on carbon and Formvar-coated, 200-mesh, nickel grids
(Electron Microscopy Sciences) and were stained with 3% uranyl acetate and
Reynolds lead citrate for visualization under a 120 kV BioTwin CM120
transmission electron microscope (Philips).
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